References
- Moore DH, Katz JS, Miller RG. A review of clinical trial designs in amyotrophic lateral sclerosis. Neurogen Dis Manage. 2011;1:481–90.
- Shefner JM. Designing clinical trials in amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am. 2008;19:495–508.
- Berry JD, Cudkowicz ME. New considerations in the design of clinical trials for amyotrophic lateral sclerosis. Clin Investig. 2011;1:1375–89.
- Gordon PH, Corcia P, Lacomblez L, Pochigaeva K, Abitbol JL, Cudkowicz M, . Defining survival as an outcome measure in amyotrophic lateral sclerosis. Arch Neurol. 2009;66:758–61.
- Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, . The ALSFRS-R predicts survival time in an ALS clinic population. Neurology. 2005;64:38–43.
- Bhatt JM, Gordon PH. Current clinical trials in amyotrophic lateral sclerosis. Expert Opin Investig Drugs. 2007;16:1197–207.
- Bensimon G. Survival endpoint: pro. Amyotroph Lateral Scler. 2002;3:S35–6.
- European Medicines Agency. European Medicines Agency guidelines. [27 August 2012]. Available from: http://www.ema.europa.eu/ema/.
- Wittkop L, Smith C, Fox Z, Sabin C, Richert L, Aboulker JP, . NEAT-WP4. Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. Clin Trials. 2010;7:19–35.
- Ferreira-González I, Permanyer-Miralda G, Busse JW, Bryant DM, Montori VM, Alonso-Coello P, . Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. J Clin Epidemiol. 2007;60:651–7.
- Freemantle N, Calvert M. Weighing the pros and cons for composite outcomes in clinical trials. J Clin Epidemiol. 2007;60:658–9.
- O’Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics. 1984;40:1079–87.
- Wong WK, Furst DE, Clements PJ, Streisand JB. Assessing disease progression using a composite endpoint. Stat Methods Med Res. 2007;16:31–49.
- Lim E, Brown A, Helmy A, Mussa S, Altman DG. Composite outcomes in cardiovascular research: a survey of randomized trials. Ann Intern Med. 2008;149:612–7.
- Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med. 1999;18:1341–54.
- Henderson R, Diggle P, Dobson A. Joint modeling of longitudinal measurements and event time data. Biostatistics. 2000;1:465–80.
- Elashoff RM, Li G, Li N. An approach to joint analysis of longitudinal measurements and competing risks failure time data. Stat Med. 2007;26:2813–35.
- Moye LA, Davis BR, Hawkins CM. Analysis of a clinical trial involving a combined mortality and adherence dependent interval censored endpoint. Stat Med. 1992;11:1705–17.
- Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, . The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011;17:1652–6.
- Rudnicki SA, Berry JD, Ingersoll E, Archibald D, Cudkowicz ME, Kerr DA, . Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler. 2013;14:44–51.
- Archibald D, Ingersoll EW, Mather JL, Schoenfeld D, Kerr D, Dong Y, . Statistical modeling to illustrate the contribution and effects of differential mortality and functional change on joint rank test outcomes in ALS. Amyotroph Lateral Scler. 2011;12:107.
- Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, . Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006;60:22–31.
- Healy BC, Schoenfeld DA. Comparison of analysis approaches for phase III clinical trials in amyotrophic lateral sclerosis. Muscle Nerve. 2012;46:506–11.
- Vonesh EF, Greene T, Schluchter MD. Shared parameter models for the joint analysis of longitudinal data and event times. Stat Med. 2006;25:143–63.
- Tseng C-H, Wong WK.Schluchter MD. Analysis of a composite endpoint with longitudinal and time-to-event data. Stat Med. 2011;30:1018–27.